LT3660509T - Ląstelių panaudojimu paremtas būdas botulino toksino aktyvumui nustatyti - Google Patents

Ląstelių panaudojimu paremtas būdas botulino toksino aktyvumui nustatyti

Info

Publication number
LT3660509T
LT3660509T LTEP19151282.1T LT19151282T LT3660509T LT 3660509 T LT3660509 T LT 3660509T LT 19151282 T LT19151282 T LT 19151282T LT 3660509 T LT3660509 T LT 3660509T
Authority
LT
Lithuania
Prior art keywords
cell
determining
based method
toxin activity
botulin toxin
Prior art date
Application number
LTEP19151282.1T
Other languages
English (en)
Inventor
Chee Gun LEE
Ji Hyun OUM
Vijayakumar AJAY
Xiangai GUI
Original Assignee
Hugel Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020180150640A external-priority patent/KR101983216B1/ko
Priority claimed from KR1020180150997A external-priority patent/KR101940500B1/ko
Priority claimed from KR1020180159701A external-priority patent/KR102251096B1/ko
Application filed by Hugel Inc. filed Critical Hugel Inc.
Publication of LT3660509T publication Critical patent/LT3660509T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1246—Rickettsiales (O)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/42—Poisoning, e.g. from bites or stings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/709—Toxin induced

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
LTEP19151282.1T 2018-11-29 2019-01-10 Ląstelių panaudojimu paremtas būdas botulino toksino aktyvumui nustatyti LT3660509T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020180150640A KR101983216B1 (ko) 2018-11-29 2018-11-29 보툴리눔 독소 활성을 결정하기 위한 항체, 및 이를 이용한 활성 측정방법
KR1020180150997A KR101940500B1 (ko) 2018-11-29 2018-11-29 보툴리눔 독소 활성을 결정하기 위한 세포주 및 이를 이용한 활성 결정 방법
KR1020180159701A KR102251096B1 (ko) 2018-12-12 2018-12-12 보툴리눔 독소 활성을 결정하는 세포 기반 방법

Publications (1)

Publication Number Publication Date
LT3660509T true LT3660509T (lt) 2022-05-10

Family

ID=65243304

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP19151282.1T LT3660509T (lt) 2018-11-29 2019-01-10 Ląstelių panaudojimu paremtas būdas botulino toksino aktyvumui nustatyti

Country Status (9)

Country Link
US (8) US10823725B2 (lt)
EP (2) EP3825689B1 (lt)
CN (4) CN114072673B (lt)
AU (2) AU2019388130B2 (lt)
BR (1) BR112021010306A2 (lt)
CA (1) CA3119962A1 (lt)
LT (1) LT3660509T (lt)
MX (1) MX2021005902A (lt)
WO (1) WO2020111449A1 (lt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220010355A1 (en) * 2020-07-10 2022-01-13 Galderma Holding SA Cell based method for determination of botulinum toxin potency based on western blotting
KR102673723B1 (ko) * 2021-05-25 2024-06-11 휴젤(주) 신경독소 역가 측정용 신규한 신경세포주
EP4526678A4 (en) * 2022-04-21 2026-07-08 Biomadison Inc CELL-BASED ASSAYS FOR BOTULIC NEUROTOXIN
CN114702600B (zh) * 2022-06-08 2022-08-23 北京大学人民医院 SNAP25蛋白Ser187位点磷酸化抑制剂的用途
US12282755B2 (en) 2022-09-10 2025-04-22 Nikolas Louis Ciminelli Generation of user interfaces from free text
CN117497037B (zh) * 2023-11-17 2024-08-16 上海倍谙基生物科技有限公司 一种基于广义线性模型的培养基组分敏感性分析方法
CN117887797B (zh) * 2023-12-27 2024-09-20 中国食品药品检定研究院 一种梭状芽胞杆菌神经毒素效价检测方法
WO2025240345A1 (en) * 2024-05-13 2025-11-20 Biomadison, Inc. Compositions and methods for characterizing botulinum neurotoxins
US20260176334A1 (en) * 2024-09-26 2026-06-25 Galderma Holding SA SNAP-25 Antibodies and Methods of Using the Same
CN119023975B (zh) * 2024-10-31 2025-04-08 兰州生物技术开发有限公司 一种测定肉毒毒素活性或snap25的方法、检测产品及抗体
CN119044509B (zh) * 2024-10-31 2025-01-28 兰州生物技术开发有限公司 测定肉毒毒素活性或突触体相关蛋白的检测产品及方法
CN119039432B (zh) * 2024-10-31 2025-01-28 兰州生物技术开发有限公司 一种检测肉毒毒素活性或突触体相关蛋白的方法和试剂盒
CN119462913B (zh) * 2025-01-14 2025-04-08 中国人民解放军军事科学院军事医学研究院 长效中和a型肉毒毒素的抗体及用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US5670484A (en) 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
ATE215832T1 (de) 1994-05-09 2002-04-15 William J Binder Botulinumtoxin zur reduktion von migraine - kopfschmerzen
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US6001067A (en) 1997-03-04 1999-12-14 Shults; Mark C. Device and method for determining analyte levels
ATE320815T1 (de) 1997-07-15 2006-04-15 Univ Colorado Verwendung einer neurotoxintherapie zur behandlung von prostata erkrankungen
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
WO2000002053A2 (en) * 1998-07-03 2000-01-13 Innogenetics N.V. Differential diagnosis of neurodegeneration
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
CA2347828A1 (en) 1998-10-27 2000-05-04 Mayo Foundation For Medical Education And Research Methods for enhancing wound healing
GB9907429D0 (en) 1999-03-31 1999-05-26 Microbiological Res Authority Modulation of C-fibre activity
GB9922554D0 (en) 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6265379B1 (en) 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6261572B1 (en) 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
US6143306A (en) 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6423319B1 (en) 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
JP4138651B2 (ja) 2001-07-27 2008-08-27 ボード オブ スーパーバイザーズ オブ ルイジアナ ステイト ユニバーシティ アンド アグリカルチュラル アンド メカニカル カレッジ にきび治療または防止のためのボツリヌス毒素
US6623742B2 (en) 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
AU2003212473A1 (en) 2002-03-01 2003-09-16 Solstice Neurosciences, Inc. Methods of treating nerve entrapment syndromes
AU2005216547B2 (en) 2004-02-24 2009-03-12 Allergan, Inc. Botulinum toxin screening assays
KR101604515B1 (ko) 2008-03-14 2016-03-17 알러간, 인코포레이티드 면역-기반 보툴리눔 독소 세로타입 a 활성 검정
MY155049A (en) 2008-03-14 2015-08-28 Allergan Inc Immuno-based botolinum toxin serotype a activity assay
KR102017327B1 (ko) * 2009-03-13 2019-09-03 알러간, 인코포레이티드 면역 기반 보툴리눔 독소 혈청형 a 활성 검정에 유용한 세포
WO2011036812A1 (ja) 2009-09-28 2011-03-31 株式会社 東芝 アリルハイドロカーボンレセプター転写活性化量を測定するための細胞、方法およびアッセイキット
EP2798077A2 (en) 2011-12-31 2014-11-05 Allergan, Inc. Highly Sensitive Cell-Based Assay to Detect the Presence of Active Botulinum Neurotoxin Serotype-A
US11976110B2 (en) 2013-06-28 2024-05-07 Merz Pharma Gmbh & Co. Kgaa Means and methods for the determination of the biological activity of neurotoxin polypeptides in cells
EP3270162B2 (en) 2013-08-09 2023-08-16 BioMadison, Inc. Botulinum toxin assay with improved sensitivity
AU2015287964A1 (en) 2014-07-07 2017-02-16 Allergan, Inc. Method of detecting cleaved SNAP25 in tissue samples
CN107001451A (zh) * 2014-07-07 2017-08-01 阿勒根公司 检测组织样品中裂解的snap25的方法
KR102514666B1 (ko) 2014-12-19 2023-03-27 메르츠 파마 게엠베하 운트 코. 카가아 세포에서 BoNT/E의 생물학적 활성의 결정을 위한 수단 및 방법
WO2018038301A1 (en) 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
KR101940500B1 (ko) * 2018-11-29 2019-01-21 주식회사 에이비바이오 보툴리눔 독소 활성을 결정하기 위한 세포주 및 이를 이용한 활성 결정 방법
KR101983216B1 (ko) * 2018-11-29 2019-05-29 주식회사 에이비바이오 보툴리눔 독소 활성을 결정하기 위한 항체, 및 이를 이용한 활성 측정방법

Also Published As

Publication number Publication date
EP3825689A2 (en) 2021-05-26
US20200340978A1 (en) 2020-10-29
US10823725B2 (en) 2020-11-03
WO2020111449A1 (ko) 2020-06-04
US10866232B2 (en) 2020-12-15
US20200340979A1 (en) 2020-10-29
CN118754976A (zh) 2024-10-11
CN114540304B (zh) 2025-11-18
CN114072673A (zh) 2022-02-18
EP3825689A3 (en) 2021-09-15
US20220003752A1 (en) 2022-01-06
CN118745222A (zh) 2024-10-08
US20250044281A1 (en) 2025-02-06
US20240077470A1 (en) 2024-03-07
AU2025230774A1 (en) 2025-10-02
US20200333325A1 (en) 2020-10-22
AU2019388130B2 (en) 2025-07-10
US20210063383A1 (en) 2021-03-04
CN114072673B (zh) 2024-07-26
AU2019388130A1 (en) 2021-06-10
US10908148B2 (en) 2021-02-02
EP3660509A1 (en) 2020-06-03
US20200173986A1 (en) 2020-06-04
US11360081B2 (en) 2022-06-14
BR112021010306A2 (pt) 2021-11-16
EP3660509B1 (en) 2022-03-09
MX2021005902A (es) 2021-06-23
CN114540304A (zh) 2022-05-27
EP3825689B1 (en) 2026-07-22
CA3119962A1 (en) 2020-06-04
US11169144B2 (en) 2021-11-09

Similar Documents

Publication Publication Date Title
IL285402A (en) Machine learning guided polypeptide analysis
EP4037552A4 (en) ANALYTE MEASUREMENT SYSTEM
EP3969834A4 (en) ANTI-DRONE SYSTEM
IL314245A (en) Methods for object detection
IL291166A (en) A method for identifying biomarkers
DK3548652T3 (da) Fremgangsmåder til proteinanalyse
PL4227023T3 (pl) Metoda otrzymywania efektywnych kosztowo elementów o złożonej geometrii
EP3761849A4 (en) PROCEDURES FOR DETECTION AND/OR PREDICTION OF SEIZURES
EP3879261A4 (en) POTENTIOMETRIC BIOSENSOR AND DETECTION METHODS
EP3273249A4 (en) Analyte measurement system and tray-identifying information search method
PL3826090T3 (pl) System i metoda wykrywania niewyrównania elektrod
EP3884177C0 (en) DETECTION DEVICE FOR BEARINGS
EP4045909A4 (en) Methods for detecting immune response
EP3610684A4 (en) SYSTEM AND METHOD FOR DETERMINING THE COLLABORATIVE POSITION
IL260854B (en) Method and system for detecting defects on a substrate
EP4042127A4 (en) LEAK DETECTION SYSTEM
IL287458A (en) Methods and systems for microsatellite analysis
IL259472B (en) An anomaly detection system and method
IL283007A (en) Cell culture system and method
IL280423A (en) A method for identifying intermediates
HUE055897T2 (hu) Eljárás C. perfringens által okozott betegségek detektálására állatokban
DK4168581T3 (da) Avanceret håndvægts-pcr til isomir-detektion
KR102272812B9 (ko) 생체분자 분석용 나노 플라즈모닉 센서, 키트 및 이를 이용한 생체분자 분석 방법
DK3717659T3 (da) Fremgangsmåde til at bestemme mikrobiel følsomhed over for antibiotiske midler
KR102358418B9 (ko) 스몰 rna 검출 방법